Literature DB >> 29555350

The multidimensional burden of atopic dermatitis: An update.

Alanna C Bridgman1, Julie K Block2, Aaron M Drucker3.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29555350     DOI： 10.1016/j.anai.2018.03.009

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN： 1081-1206            Impact factor:   6.347


× No keyword cloud information.
  6 in total

1.  Quercetin Improves Inflammation, Oxidative Stress, and Impaired Wound Healing in Atopic Dermatitis Model of Human Keratinocytes.

Authors:  Burcin Beken; Riza Serttas; Mehtap Yazicioglu; Kader Turkekul; Suat Erdogan
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2020-05-21       Impact factor: 1.349

2.  Canadian Burden of Skin Disease From 1990 to 2017: Results From the Global Burden of Disease 2017 Study [Formula: see text].

Authors:  Alanna C Bridgman; Christina Fitzmaurice; Robert P Dellavalle; Chante Karimkhani Aksut; Ayman Grada; Mohsen Naghavi; Navid Manafi; Andrew T Olagunju; Tinuke O Olagunju; Ranjani Somayaji; Aaron M Drucker
Journal:  J Cutan Med Surg       Date:  2020-01-29       Impact factor: 2.092

3.  Antipruritic Effect of Ethyl Acetate Extract from Fructus cnidii in Mice with 2,4-Dinitrofluorobenzene-Induced Atopic Dermatitis.

Authors:  Xi Chen; Chan Zhu; Yingge Zhang; Niuniu Yang; Hao Shi; Weiwei Yang; Yan Yang; Jianqiang Liang; Liuzhi Chen; Xueying Zeng; Rijin Cai; Guanyi Wu; Zongxiang Tang
Journal:  Evid Based Complement Alternat Med       Date:  2020-05-06       Impact factor: 2.629

Review 4.  Characteristics, mechanism, and management of pain in atopic dermatitis: A literature review.

Authors:  Jia-Xin Li; Rui-Jia Dong; Yue-Ping Zeng
Journal:  Clin Transl Allergy       Date:  2021-12       Impact factor: 5.871

Review 5.  Use of Dexpanthenol for Atopic Dermatitis-Benefits and Recommendations Based on Current Evidence.

Authors:  Yoon Sun Cho; Hye One Kim; Seung Man Woo; Dong Hun Lee
Journal:  J Clin Med       Date:  2022-07-06       Impact factor: 4.964

6.  Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies.

Authors:  K Kabashima; T Matsumura; H Komazaki; M Kawashima
Journal:  Br J Dermatol       Date:  2021-12-21       Impact factor: 11.113
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.